aluates Reports

$ 0.0

Automative

Human Coagulation Factor VII- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Published Date: August 2025

Report Code: QYRE-Auto-25N8769

Global Human Coagulation Factor VII Market Outlook 2022

BUY CHAPTERS

Human Coagulation Factor VII- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Code: QYRE-Auto-25N8769

Report

August 2025

Pages:88

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

NovoNordisk

LFB SA HEMA Biologics

AryoGen Pharmed

Generium

Human Coagulation Factor VII- Market Size

The global market for Human Coagulation Factor VII was estimated to be worth US$ 1251 million in 2024 and is forecast to a readjusted size of US$ 1608 million by 2031 with a CAGR of 3.7% during the forecast period 2025-2031.

Human Coagulation Factor VII- Market

Human Coagulation Factor VII is a protein that plays a crucial role in the blood clotting process (hemostasis). It is one of the key components of the extrinsic pathway of the coagulation cascade, which is activated when tissue damage occurs. Factor VII works by binding to tissue factor (TF) exposed at the site of injury, forming a complex that activates other clotting factors (such as Factor X and Factor IX), ultimately leading to the formation of a blood clot.

In its recombinant form, Recombinant Human Coagulation Factor VIIa (rFVIIa) is used as a medication to help control bleeding, particularly in patients with hemophilia or other bleeding disorders who have developed inhibitors to conventional therapies.

Drivers of the Recombinant Human Coagulation Factor VII Market:

Rising Prevalence of Hemophilia and Bleeding Disorders: Recombinant Factor VIIa is primarily used in treating hemophilia, especially in patients with inhibitors to Factor VIII or IX. The growing global incidence of hemophilia and other bleeding disorders is a major driver of market demand.

Advancements in Recombinant Technology: Ongoing improvements in biotechnology have led to the development of safer and more effective recombinant coagulation products. These advancements reduce the risk of bloodborne pathogen transmission, increasing their adoption over plasma-derived alternatives.

Increased Use in Trauma and Surgery: Recombinant Factor VIIa is also used in managing severe bleeding during trauma and surgical procedures, further expanding its clinical applications and boosting demand, particularly in emergency care settings.

Rising Adoption in Off-Label Uses: While its primary indication is for hemophilia, rFVIIa is increasingly being used off-label to manage uncontrolled bleeding in non-hemophiliac patients, particularly in critical care and trauma settings. This broadens its potential market.

Favorable Reimbursement Policies in Developed Regions: In regions like North America and Europe, the availability of comprehensive insurance and reimbursement for advanced therapies like rFVIIa makes these treatments more accessible to patients, supporting market growth.

Challenges of the Recombinant Human Coagulation Factor VII Market:

High Cost of Treatment: Recombinant Factor VIIa therapy is expensive, which can limit access, especially in low-income countries and regions without robust healthcare funding or insurance coverage.

Potential for Off-Label Use Concerns: Despite its increasing use in off-label applications, concerns about the safety and efficacy of rFVIIa in non-hemophilia patients have led to caution in its broader application. Regulatory scrutiny on off-label use may impact market expansion.

Limited Awareness and Access in Developing Regions: In many developing countries, awareness of recombinant therapies for hemophilia is limited, and access to advanced treatments is constrained by inadequate healthcare infrastructure and funding.

Competition from Alternative Therapies: Emerging gene therapies, extended half-life clotting factors, and other innovative treatments for hemophilia may compete with or reduce the demand for rFVIIa in the future. These newer therapies promise more long-term efficacy or convenience.

Regulatory Challenges: The stringent regulatory approval process for biologics, along with the ongoing need for post-market surveillance, can slow down the introduction of new products or indications, impacting the pace of market growth.

The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.

This report aims to provide a comprehensive presentation of the global market for Human Coagulation Factor VII, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Coagulation Factor VII by region & country, by Type, and by Application.

The Human Coagulation Factor VII market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Coagulation Factor VII.

Market Segmentation

Scope of Human Coagulation Factor VII- Market Report

Report Metric	Details
Report Name	Human Coagulation Factor VII- Market
Forecasted market size in 2031	US$ 1608 million
CAGR	3.7%
Forecasted years	2025 - 2031
Segment by Type	Prefilled Syringe Vial
Segment by Application	Congenital Hemophilia Acquired Hemophilia Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	NovoNordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Coagulation Factor VII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Human Coagulation Factor VII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Human Coagulation Factor VII in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Human Coagulation Factor VII- Market size in 2031?

Ans: The Human Coagulation Factor VII- Market size in 2031 will be US$ 1608 million.

What is the market share of major companies in Human Coagulation Factor VII- Market?

Ans: The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%.

What is the Human Coagulation Factor VII- Market share by region?

Ans: North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.

Who are the main players in the Human Coagulation Factor VII- Market report?

Ans: The main players in the Human Coagulation Factor VII- Market are NovoNordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM

What are the Application segmentation covered in the Human Coagulation Factor VII- Market report?

Ans: The Applications covered in the Human Coagulation Factor VII- Market report are Congenital Hemophilia, Acquired Hemophilia, Other

What are the Type segmentation covered in the Human Coagulation Factor VII- Market report?

Ans: The Types covered in the Human Coagulation Factor VII- Market report are Prefilled Syringe, Vial

Recommended Reports

Coagulation Devices

Hemophilia Treatments

Blood Coagulation Solutions

1 Market Overview

1.1 Human Coagulation Factor VII Product Introduction

1.2 Global Human Coagulation Factor VII Market Size Forecast

1.2.1 Global Human Coagulation Factor VII Sales Value (2020-2031)

1.2.2 Global Human Coagulation Factor VII Sales Volume (2020-2031)

1.2.3 Global Human Coagulation Factor VII Sales Price (2020-2031)

1.3 Human Coagulation Factor VII Market Trends & Drivers

1.3.1 Human Coagulation Factor VII Industry Trends

1.3.2 Human Coagulation Factor VII Market Drivers & Opportunity

1.3.3 Human Coagulation Factor VII Market Challenges

1.3.4 Human Coagulation Factor VII Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Human Coagulation Factor VII Players Revenue Ranking (2024)

2.2 Global Human Coagulation Factor VII Revenue by Company (2020-2025)

2.3 Global Human Coagulation Factor VII Players Sales Volume Ranking (2024)

2.4 Global Human Coagulation Factor VII Sales Volume by Company Players (2020-2025)

2.5 Global Human Coagulation Factor VII Average Price by Company (2020-2025)

2.6 Key Manufacturers Human Coagulation Factor VII Manufacturing Base and Headquarters

2.7 Key Manufacturers Human Coagulation Factor VII Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Human Coagulation Factor VII

2.9 Human Coagulation Factor VII Market Competitive Analysis

2.9.1 Human Coagulation Factor VII Market Concentration Rate (2020-2025)

2.9.2 Global 5 and 10 Largest Manufacturers by Human Coagulation Factor VII Revenue in 2024

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Coagulation Factor VII as of 2024)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Prefilled Syringe

3.1.2 Vial

3.2 Global Human Coagulation Factor VII Sales Value by Type

3.2.1 Global Human Coagulation Factor VII Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Human Coagulation Factor VII Sales Value, by Type (2020-2031)

3.2.3 Global Human Coagulation Factor VII Sales Value, by Type (%) (2020-2031)

3.3 Global Human Coagulation Factor VII Sales Volume by Type

3.3.1 Global Human Coagulation Factor VII Sales Volume by Type (2020 VS 2024 VS 2031)

3.3.2 Global Human Coagulation Factor VII Sales Volume, by Type (2020-2031)

3.3.3 Global Human Coagulation Factor VII Sales Volume, by Type (%) (2020-2031)

3.4 Global Human Coagulation Factor VII Average Price by Type (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Congenital Hemophilia

4.1.2 Acquired Hemophilia

4.1.3 Other

4.2 Global Human Coagulation Factor VII Sales Value by Application

4.2.1 Global Human Coagulation Factor VII Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Human Coagulation Factor VII Sales Value, by Application (2020-2031)

4.2.3 Global Human Coagulation Factor VII Sales Value, by Application (%) (2020-2031)

4.3 Global Human Coagulation Factor VII Sales Volume by Application

4.3.1 Global Human Coagulation Factor VII Sales Volume by Application (2020 VS 2024 VS 2031)

4.3.2 Global Human Coagulation Factor VII Sales Volume, by Application (2020-2031)

4.3.3 Global Human Coagulation Factor VII Sales Volume, by Application (%) (2020-2031)

4.4 Global Human Coagulation Factor VII Average Price by Application (2020-2031)

5 Segmentation by Region

5.1 Global Human Coagulation Factor VII Sales Value by Region

5.1.1 Global Human Coagulation Factor VII Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Human Coagulation Factor VII Sales Value by Region (2020-2025)

5.1.3 Global Human Coagulation Factor VII Sales Value by Region (2026-2031)

5.1.4 Global Human Coagulation Factor VII Sales Value by Region (%), (2020-2031)

5.2 Global Human Coagulation Factor VII Sales Volume by Region

5.2.1 Global Human Coagulation Factor VII Sales Volume by Region: 2020 VS 2024 VS 2031

5.2.2 Global Human Coagulation Factor VII Sales Volume by Region (2020-2025)

5.2.3 Global Human Coagulation Factor VII Sales Volume by Region (2026-2031)

5.2.4 Global Human Coagulation Factor VII Sales Volume by Region (%), (2020-2031)

5.3 Global Human Coagulation Factor VII Average Price by Region (2020-2031)

5.4 North America

5.4.1 North America Human Coagulation Factor VII Sales Value, 2020-2031

5.4.2 North America Human Coagulation Factor VII Sales Value by Country (%), 2024 VS 2031

5.5 Europe

5.5.1 Europe Human Coagulation Factor VII Sales Value, 2020-2031

5.5.2 Europe Human Coagulation Factor VII Sales Value by Country (%), 2024 VS 2031

5.6 Asia Pacific

5.6.1 Asia Pacific Human Coagulation Factor VII Sales Value, 2020-2031

5.6.2 Asia Pacific Human Coagulation Factor VII Sales Value by Region (%), 2024 VS 2031

5.7 South America

5.7.1 South America Human Coagulation Factor VII Sales Value, 2020-2031

5.7.2 South America Human Coagulation Factor VII Sales Value by Country (%), 2024 VS 2031

5.8 Middle East & Africa

5.8.1 Middle East & Africa Human Coagulation Factor VII Sales Value, 2020-2031

5.8.2 Middle East & Africa Human Coagulation Factor VII Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Human Coagulation Factor VII Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Human Coagulation Factor VII Sales Value

6.2.1 Key Countries/Regions Human Coagulation Factor VII Sales Value, 2020-2031

6.2.2 Key Countries/Regions Human Coagulation Factor VII Sales Volume, 2020-2031

6.3 United States

6.3.1 United States Human Coagulation Factor VII Sales Value, 2020-2031

6.3.2 United States Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Human Coagulation Factor VII Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Human Coagulation Factor VII Sales Value, 2020-2031

6.4.2 Europe Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Human Coagulation Factor VII Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Human Coagulation Factor VII Sales Value, 2020-2031

6.5.2 China Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

6.5.3 China Human Coagulation Factor VII Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Human Coagulation Factor VII Sales Value, 2020-2031

6.6.2 Japan Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Human Coagulation Factor VII Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Human Coagulation Factor VII Sales Value, 2020-2031

6.7.2 South Korea Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Human Coagulation Factor VII Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Human Coagulation Factor VII Sales Value, 2020-2031

6.8.2 Southeast Asia Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Human Coagulation Factor VII Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Human Coagulation Factor VII Sales Value, 2020-2031

6.9.2 India Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

6.9.3 India Human Coagulation Factor VII Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 NovoNordisk

7.1.1 NovoNordisk Company Information

7.1.2 NovoNordisk Introduction and Business Overview

7.1.3 NovoNordisk Human Coagulation Factor VII Sales, Revenue, Price and Gross Margin (2020-2025)

7.1.4 NovoNordisk Human Coagulation Factor VII Product Offerings

7.1.5 NovoNordisk Recent Development

7.2 LFB SA HEMA Biologics

7.2.1 LFB SA HEMA Biologics Company Information

7.2.2 LFB SA HEMA Biologics Introduction and Business Overview

7.2.3 LFB SA HEMA Biologics Human Coagulation Factor VII Sales, Revenue, Price and Gross Margin (2020-2025)

7.2.4 LFB SA HEMA Biologics Human Coagulation Factor VII Product Offerings

7.2.5 LFB SA HEMA Biologics Recent Development

7.3 AryoGen Pharmed

7.3.1 AryoGen Pharmed Company Information

7.3.2 AryoGen Pharmed Introduction and Business Overview

7.3.3 AryoGen Pharmed Human Coagulation Factor VII Sales, Revenue, Price and Gross Margin (2020-2025)

7.3.4 AryoGen Pharmed Human Coagulation Factor VII Product Offerings

7.3.5 AryoGen Pharmed Recent Development

7.4 GENERIUM

7.4.1 GENERIUM Company Information

7.4.2 GENERIUM Introduction and Business Overview

7.4.3 GENERIUM Human Coagulation Factor VII Sales, Revenue, Price and Gross Margin (2020-2025)

7.4.4 GENERIUM Human Coagulation Factor VII Product Offerings

7.4.5 GENERIUM Recent Development

8 Industry Chain Analysis

8.1 Human Coagulation Factor VII Industrial Chain

8.2 Human Coagulation Factor VII Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Human Coagulation Factor VII Sales Model

8.5.2 Sales Channel

8.5.3 Human Coagulation Factor VII Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

NovoNordisk

LFB SA HEMA Biologics

AryoGen Pharmed

Generium

List of Tables

Table 1. Human Coagulation Factor VII Market Trends

Table 2. Human Coagulation Factor VII Market Drivers & Opportunity

Table 3. Human Coagulation Factor VII Market Challenges

Table 4. Human Coagulation Factor VII Market Restraints

Table 5. Global Human Coagulation Factor VII Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Human Coagulation Factor VII Revenue Market Share by Company (2020-2025)

Table 7. Global Human Coagulation Factor VII Sales Volume by Company (2020-2025) & (K Units)

Table 8. Global Human Coagulation Factor VII Sales Volume Market Share by Company (2020-2025)

Table 9. Global Market Human Coagulation Factor VII Price by Company (2020-2025) & (US$/Unit)

Table 10. Key Manufacturers Human Coagulation Factor VII Manufacturing Base and Headquarters

Table 11. Key Manufacturers Human Coagulation Factor VII Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Human Coagulation Factor VII

Table 13. Global Human Coagulation Factor VII Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Coagulation Factor VII as of 2024)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Human Coagulation Factor VII Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 17. Global Human Coagulation Factor VII Sales Value by Type (2020-2025) & (US$ Million)

Table 18. Global Human Coagulation Factor VII Sales Value by Type (2026-2031) & (US$ Million)

Table 19. Global Human Coagulation Factor VII Sales Market Share in Value by Type (2020-2025)

Table 20. Global Human Coagulation Factor VII Sales Market Share in Value by Type (2026-2031)

Table 21. Global Human Coagulation Factor VII Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)

Table 22. Global Human Coagulation Factor VII Sales Volume by Type (2020-2025) & (K Units)

Table 23. Global Human Coagulation Factor VII Sales Volume by Type (2026-2031) & (K Units)

Table 24. Global Human Coagulation Factor VII Sales Market Share in Volume by Type (2020-2025)

Table 25. Global Human Coagulation Factor VII Sales Market Share in Volume by Type (2026-2031)

Table 26. Global Human Coagulation Factor VII Price by Type (2020-2025) & (US$/Unit)

Table 27. Global Human Coagulation Factor VII Price by Type (2026-2031) & (US$/Unit)

Table 28. Global Human Coagulation Factor VII Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 29. Global Human Coagulation Factor VII Sales Value by Application (2020-2025) & (US$ Million)

Table 30. Global Human Coagulation Factor VII Sales Value by Application (2026-2031) & (US$ Million)

Table 31. Global Human Coagulation Factor VII Sales Market Share in Value by Application (2020-2025)

Table 32. Global Human Coagulation Factor VII Sales Market Share in Value by Application (2026-2031)

Table 33. Global Human Coagulation Factor VII Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)

Table 34. Global Human Coagulation Factor VII Sales Volume by Application (2020-2025) & (K Units)

Table 35. Global Human Coagulation Factor VII Sales Volume by Application (2026-2031) & (K Units)

Table 36. Global Human Coagulation Factor VII Sales Market Share in Volume by Application (2020-2025)

Table 37. Global Human Coagulation Factor VII Sales Market Share in Volume by Application (2026-2031)

Table 38. Global Human Coagulation Factor VII Price by Application (2020-2025) & (US$/Unit)

Table 39. Global Human Coagulation Factor VII Price by Application (2026-2031) & (US$/Unit)

Table 40. Global Human Coagulation Factor VII Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 41. Global Human Coagulation Factor VII Sales Value by Region (2020-2025) & (US$ Million)

Table 42. Global Human Coagulation Factor VII Sales Value by Region (2026-2031) & (US$ Million)

Table 43. Global Human Coagulation Factor VII Sales Value by Region (2020-2025) & (%)

Table 44. Global Human Coagulation Factor VII Sales Value by Region (2026-2031) & (%)

Table 45. Global Human Coagulation Factor VII Sales Volume by Region (K Units): 2020 VS 2024 VS 2031

Table 46. Global Human Coagulation Factor VII Sales Volume by Region (2020-2025) & (K Units)

Table 47. Global Human Coagulation Factor VII Sales Volume by Region (2026-2031) & (K Units)

Table 48. Global Human Coagulation Factor VII Sales Volume by Region (2020-2025) & (%)

Table 49. Global Human Coagulation Factor VII Sales Volume by Region (2026-2031) & (%)

Table 50. Global Human Coagulation Factor VII Average Price by Region (2020-2025) & (US$/Unit)

Table 51. Global Human Coagulation Factor VII Average Price by Region (2026-2031) & (US$/Unit)

Table 52. Key Countries/Regions Human Coagulation Factor VII Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 53. Key Countries/Regions Human Coagulation Factor VII Sales Value, (2020-2025) & (US$ Million)

Table 54. Key Countries/Regions Human Coagulation Factor VII Sales Value, (2026-2031) & (US$ Million)

Table 55. Key Countries/Regions Human Coagulation Factor VII Sales Volume, (2020-2025) & (K Units)

Table 56. Key Countries/Regions Human Coagulation Factor VII Sales Volume, (2026-2031) & (K Units)

Table 57. NovoNordisk Company Information

Table 58. NovoNordisk Introduction and Business Overview

Table 59. NovoNordisk Human Coagulation Factor VII Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 60. NovoNordisk Human Coagulation Factor VII Product Offerings

Table 61. NovoNordisk Recent Development

Table 62. LFB SA HEMA Biologics Company Information

Table 63. LFB SA HEMA Biologics Introduction and Business Overview

Table 64. LFB SA HEMA Biologics Human Coagulation Factor VII Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 65. LFB SA HEMA Biologics Human Coagulation Factor VII Product Offerings

Table 66. LFB SA HEMA Biologics Recent Development

Table 67. AryoGen Pharmed Company Information

Table 68. AryoGen Pharmed Introduction and Business Overview

Table 69. AryoGen Pharmed Human Coagulation Factor VII Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 70. AryoGen Pharmed Human Coagulation Factor VII Product Offerings

Table 71. AryoGen Pharmed Recent Development

Table 72. GENERIUM Company Information

Table 73. GENERIUM Introduction and Business Overview

Table 74. GENERIUM Human Coagulation Factor VII Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. GENERIUM Human Coagulation Factor VII Product Offerings

Table 76. GENERIUM Recent Development

Table 77. Key Raw Materials Lists

Table 78. Raw Materials Key Suppliers Lists

Table 79. Human Coagulation Factor VII Downstream Customers

Table 80. Human Coagulation Factor VII Distributors List

Table 81. Research Programs/Design for This Report

Table 82. Key Data Information from Secondary Sources

Table 83. Key Data Information from Primary Sources

List of Figures

Figure 1. Human Coagulation Factor VII Product Picture

Figure 2. Global Human Coagulation Factor VII Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Human Coagulation Factor VII Sales Value (2020-2031) & (US$ Million)

Figure 4. Global Human Coagulation Factor VII Sales Volume (2020-2031) & (K Units)

Figure 5. Global Human Coagulation Factor VII Sales Price (2020-2031) & (US$/Unit)

Figure 6. Human Coagulation Factor VII Report Years Considered

Figure 7. Global Human Coagulation Factor VII Players Revenue Ranking (2024) & (US$ Million)

Figure 8. Global Human Coagulation Factor VII Players Sales Volume Ranking (2024) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Human Coagulation Factor VII Revenue in 2024

Figure 10. Human Coagulation Factor VII Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 11. Prefilled Syringe Picture

Figure 12. Vial Picture

Figure 13. Global Human Coagulation Factor VII Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 14. Global Human Coagulation Factor VII Sales Value Market Share by Type, 2024 & 2031

Figure 15. Global Human Coagulation Factor VII Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)

Figure 16. Global Human Coagulation Factor VII Sales Volume Market Share by Type, 2024 & 2031

Figure 17. Global Human Coagulation Factor VII Price by Type (2020-2031) & (US$/Unit)

Figure 18. Product Picture of Congenital Hemophilia

Figure 19. Product Picture of Acquired Hemophilia

Figure 20. Product Picture of Other

Figure 21. Global Human Coagulation Factor VII Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 22. Global Human Coagulation Factor VII Sales Value Market Share by Application, 2024 & 2031

Figure 23. Global Human Coagulation Factor VII Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)

Figure 24. Global Human Coagulation Factor VII Sales Volume Market Share by Application, 2024 & 2031

Figure 25. Global Human Coagulation Factor VII Price by Application (2020-2031) & (US$/Unit)

Figure 26. North America Human Coagulation Factor VII Sales Value (2020-2031) & (US$ Million)

Figure 27. North America Human Coagulation Factor VII Sales Value by Country (%), 2024 VS 2031

Figure 28. Europe Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 29. Europe Human Coagulation Factor VII Sales Value by Country (%), 2024 VS 2031

Figure 30. Asia Pacific Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 31. Asia Pacific Human Coagulation Factor VII Sales Value by Region (%), 2024 VS 2031

Figure 32. South America Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 33. South America Human Coagulation Factor VII Sales Value by Country (%), 2024 VS 2031

Figure 34. Middle East & Africa Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 35. Middle East & Africa Human Coagulation Factor VII Sales Value by Country (%), 2024 VS 2031

Figure 36. Key Countries/Regions Human Coagulation Factor VII Sales Value (%), (2020-2031)

Figure 37. Key Countries/Regions Human Coagulation Factor VII Sales Volume (%), (2020-2031)

Figure 38. United States Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 39. United States Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

Figure 40. United States Human Coagulation Factor VII Sales Value by Application (%), 2024 VS 2031

Figure 41. Europe Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 42. Europe Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

Figure 43. Europe Human Coagulation Factor VII Sales Value by Application (%), 2024 VS 2031

Figure 44. China Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 45. China Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

Figure 46. China Human Coagulation Factor VII Sales Value by Application (%), 2024 VS 2031

Figure 47. Japan Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 48. Japan Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

Figure 49. Japan Human Coagulation Factor VII Sales Value by Application (%), 2024 VS 2031

Figure 50. South Korea Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 51. South Korea Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

Figure 52. South Korea Human Coagulation Factor VII Sales Value by Application (%), 2024 VS 2031

Figure 53. Southeast Asia Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 54. Southeast Asia Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

Figure 55. Southeast Asia Human Coagulation Factor VII Sales Value by Application (%), 2024 VS 2031

Figure 56. India Human Coagulation Factor VII Sales Value, (2020-2031) & (US$ Million)

Figure 57. India Human Coagulation Factor VII Sales Value by Type (%), 2024 VS 2031

Figure 58. India Human Coagulation Factor VII Sales Value by Application (%), 2024 VS 2031

Figure 59. Human Coagulation Factor VII Industrial Chain

Figure 60. Human Coagulation Factor VII Manufacturing Cost Structure

Figure 61. Channels of Distribution (Direct Sales, and Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Recombinant Human Coagulation VIIa Market Research Report 2025

Global Human Thrombin Market Research Report 2024

Coagulation Factor VIIa Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Recombinant Human Thrombin Protein Market Research Report 2024

Thrombin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Recombinant Human Thrombin for Surgical Hemostasis Market Research Report 2024

Global Eptacog Alfa rFVIIa Market Research Report 2025

Human Coagulation Factor Ⅷ Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Blood Coagulation Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Coagulation Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Human Coagulation Factor IX Market Research Report 2024

Global Factor Xa Market Research Report 2025

Global Human Fibrinogen Market Insights Forecast to 2030

Coagulation Factor IX Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Clotting Factor Market Research Report 2025

Antihemophilic Factor Recombinant Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Recombinant Coagulation Factors Market Insights Forecast to 2030

Global Topical Recombinant Human Thrombin Market Research Report 2024

Eptacog Alfa Recombinant Human Coagulation Factor VIIa Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions